510 related articles for article (PubMed ID: 30103096)
1. Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057.
Reck M; Brahmer J; Bennett B; Taylor F; Penrod JR; DeRosa M; Dastani H; Spigel DR; Gralla RJ
Eur J Cancer; 2018 Oct; 102():23-30. PubMed ID: 30103096
[TBL] [Abstract][Full Text] [Related]
2. Three-year follow-up and patient-reported outcomes from CheckMate 078: Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer.
Chang J; Wu YL; Lu S; Wang J; Mok T; Zhang L; Feng J; Wu L; Tu HY; Zhang Y; Luft A; Zhou JY; Ma Z; Lu Y; Hu C; Shi Y; Poddubskaya E; Soo RA; Chia YH; Penrod JR; Taylor F; Lawrance R; Blum SI; Sun X; Juarez-Garcia A; Moreno-Koehler A; Li A; Li A; Cheng Y
Lung Cancer; 2022 Mar; 165():71-81. PubMed ID: 35093625
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab Versus Docetaxel for Previously Treated Advanced Non-Small Cell Lung Cancer in China: A Cost-Effectiveness Analysis.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
Clin Drug Investig; 2020 Feb; 40(2):129-137. PubMed ID: 31679121
[TBL] [Abstract][Full Text] [Related]
4. Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M; Xiao H; Blum SI; Elimova E; Cella D; Shitara K; Ajani JA; Janjigian YY; Garrido M; Shen L; Yamaguchi K; Liu T; Schenker M; Kowalyszyn R; Bragagnoli AC; Bruges R; Montesarchio V; Pazo-Cid R; Hunter S; Davenport E; Wang J; Kondo K; Li M; Wyrwicz L
J Clin Oncol; 2023 Dec; 41(35):5388-5399. PubMed ID: 37713657
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.
Wang Y; Hao Q; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Wu D; Long J; Zhang Z; Fang J
Anticancer Drugs; 2024 Jun; 35(5):412-417. PubMed ID: 38240789
[TBL] [Abstract][Full Text] [Related]
6. Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
Saito Y; Sasaki S; Oikado K; Tominaga J; Sata M; Sakai F; Kato T; Iwasawa T; Kenmotsu H; Kusumoto M; Baba T; Endo M; Fujiwara Y; Sugiura H; Yanagawa N; Ito Y; Sakamoto T; Ohe Y; Kuwano K
Cancer Sci; 2021 Apr; 112(4):1495-1505. PubMed ID: 33098725
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients.
Paracha N; Abdulla A; MacGilchrist KS
Health Qual Life Outcomes; 2018 Sep; 16(1):179. PubMed ID: 30208899
[TBL] [Abstract][Full Text] [Related]
8. Combi-TED: a new trial testing Tedopi
Landi L; Delmonte A; Bonetti A; Pasello G; Metro G; Mazzoni F; Borra G; Giannarelli D; Andrikou K; Mangiola D; Gori S; D'Andrea MR; Minuti G; Resuli B; Laudisi A; Vidiri A; Conti L; Cappuzzo F
Future Oncol; 2022 Dec; 18(40):4457-4464. PubMed ID: 36946237
[TBL] [Abstract][Full Text] [Related]
9. Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer.
Ang YL; Lim JS; Soo RA
Onco Targets Ther; 2016; 9():3187-95. PubMed ID: 27313464
[TBL] [Abstract][Full Text] [Related]
10. Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature.
Leitinger M; Varosanec MV; Pikija S; Wass RE; Bandke D; Weis S; Studnicka M; Grinzinger S; McCoy MR; Hauer L; Sellner J
Front Immunol; 2018; 9():108. PubMed ID: 29441072
[TBL] [Abstract][Full Text] [Related]
11. New targeted treatments for non-small-cell lung cancer - role of nivolumab.
Zago G; Muller M; van den Heuvel M; Baas P
Biologics; 2016; 10():103-17. PubMed ID: 27536062
[TBL] [Abstract][Full Text] [Related]
12. Does caring for patients with advanced non-small cell lung cancer affect health-related quality of life of caregivers? A multicenter, cross-sectional study.
Yang Y; Liu L; Chen J; Gan Y; Su C; Zhang H; Long E; Yan F; Chen Y
BMC Public Health; 2024 Jan; 24(1):224. PubMed ID: 38238722
[TBL] [Abstract][Full Text] [Related]
13. Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer. Reply.
Provencio M; Massuti B; Romero A
N Engl J Med; 2023 Oct; 389(16):1534-1535. PubMed ID: 37851886
[No Abstract] [Full Text] [Related]
14. Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer.
Verma S; Vincent M; Breadner D
N Engl J Med; 2023 Oct; 389(16):1534. PubMed ID: 37851885
[No Abstract] [Full Text] [Related]
15. The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.
Cella D; Choueiri TK; Hamilton M; Blum SI; Ivanescu C; Karu K; Ejzykowicz F; Motzer RJ
Oncologist; 2024 Jan; ():. PubMed ID: 38280218
[TBL] [Abstract][Full Text] [Related]
16. Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials.
Lord-Bessen J; Signorovitch J; Yang M; Georgieva M; Roydhouse J
JNCI Cancer Spectr; 2023 Mar; 7(2):. PubMed ID: 36661326
[TBL] [Abstract][Full Text] [Related]
17. Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Orozco-Leal G; Johnson EE; Hosseinijebeli S; Robinson T; Homer T; Eastaugh CH; Richmond C; Tanner L; Meader N; Kenny R; Wallace SA; Rice S
Pharmacoeconomics; 2024 Feb; 42(2):133-136. PubMed ID: 37985576
[No Abstract] [Full Text] [Related]
18. A randomized trial of weekly symptom telemonitoring in advanced lung cancer.
Yount SE; Rothrock N; Bass M; Beaumont JL; Pach D; Lad T; Patel J; Corona M; Weiland R; Del Ciello K; Cella D
J Pain Symptom Manage; 2014 Jun; 47(6):973-89. PubMed ID: 24210705
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.
Claassens L; van Meerbeeck J; Coens C; Quinten C; Ghislain I; Sloan EK; Wang XS; Velikova G; Bottomley A
J Clin Oncol; 2011 May; 29(15):2104-20. PubMed ID: 21464420
[TBL] [Abstract][Full Text] [Related]
20. Response to "Immune-mediated cholangitis: is it always nivolumab's fault?".
Kashima J; Okuma Y
Cancer Immunol Immunother; 2018 Aug; 67(8):1329-1330. PubMed ID: 29700568
[No Abstract] [Full Text] [Related]
[Next] [New Search]
